Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer

New peer-reviewed research published in the Journal of the American Medical Association (JAMA) Oncology validates the efficacy of MyProstateScore 2.0 (MPS2). The findings signify a major advancement in the ability to make highly accurate, comprehensive and personalized predictions by raising the performance standard for urine biomarker tests intended to detect clinically significant prostate cancer.  

Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone

Both Caucasian and African American men with baseline PSA values between 1.5 and 4.0 ng/mL are at increased risk for future prostate cancer compared with those who have an initial PSA value below the 1.5 ng/mL threshold. Based on a growing body of literature and this analysis, it is recommended that a first PSA test threshold of 1.5 ng/mL and above, or somewhere between 1.5 and 4.0 ng/mL, represent the Early-Warning PSA Zone (EWP Zone). 

Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting

This study looked at the hereditary cancer risk assessment, education, and testing of patients in the community-based setting and found that genetic testing led to the identification of significant cancer risks that would not have been recognized without the multi-gene panel test. 

Confirm mdx’s Effectiviness in Risk Stratification in African American Men

In studying 211 African American men, this research found that Confirm mdx is an effective tool in identifying high risk African American men who previously had a negative biopsy.   

Diagnosing hereditary cancer predisposition in men with prostate cancer

This study looks at  men with prostate cancer who underwent clinical multigene panel testing.  The study found that multigene panel testing as the primary genetic testing approach for hereditary prostate cancer is effective and should be a consideration for germline testing in men with prostate cancer.

Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease

This study found the Decipher test to be effective in identifying African American men who are at higher genomic risk for more aggressive prostate cancer. The study concludes that risk stratifying this segment of men can lead to more effective medical interventions earlier in the disease progression.

A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men

The 4Kscore test accurately detects aggressive prostate cancer and reduces unnecessary biopsies yet, its performance in African American men has been unknown. We assessed test performance in a cohort of men with a large African American representation and confirmed that the 4Kscore test accurately predicts aggressive prostate cancer for biopsy decision making in African American […]

Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection

The objective of the present study was to evaluate the diagnostic potential of p2PSA, %p2PSA, phi, and phi density (PHID) as independent biomarkers and in combination with other demographic and clinical parameters, to predict overall and clinically significant PCa. The ability of p2PSA and its derivatives to discriminate HGPIN at biopsy was evaluated.